Effect of Preoperative Intravitreal Bevacizumab on the Success of Trabeculectomy with Mitomycin C in Neovascular Glaucoma by Niazi, Fuad Ahmad Khan




Effect of Preoperative Intravitreal Bevacizumab on the 
Success of Trabeculectomy with Mitomycin C in 
Neovascular Glaucoma. 
 
Fuad Ahmad Khan Niazi*, Muhammad Imran Janjua*, Muhammad Rizwan Khan*, 
 Muhammad Afzal Khan Niazi,** 
*Department of Ophthalmology, Holy Family Hospital and Rawalpindi Medical College; **Department of 
Ophthalmology, Wah Medical College, Wah Cantt 
 
Abstract 
Background: To assess the effect of preoperative 
Intravitreal Bevacizumab on the success of 
Trabeculectomy with Mitomycin C in neovascular 
glaucoma. 
Methods: In this case control study 21 eyes of 21 
patients with neovascular glaucoma irrespective of 
the primary pathology were selected.   All of them 
were given Intravitreal Bevacizumab one to two 
weeks prior to a conventional primary 
trabeculectomy with Mitomycin C. All eyes were 
then followed after 01 month for the surgical 
outcome of success, which was an IOP of less than 21 
mmHg without medication with a functioning bleb. 
Intravitreal Bevacizumab was given in a dose of 
1.25mg/.05ml using a 29 gauge insulin syringe , 
approximately one to two weeks prior to a planned 
primary trabeculectomy.The trabeculectomy 
procedures were all performed under local 
anesthesia (facial and peribulbar block). A fornix 
based conjunctival flap was lifted and a 4mm x 2mm 
rectangular sclera flap raised and Mitomycin C,  in a 
concentration of 0.5mg/ml applied beneath the 
scleral and conjunctival flaps using a soaked sponge 
for 4 to 5 minutes and later washed with 20 ml 
Ringer’s Lactate solution. A sclerotomy was then 
fashioned measuring 1.5mm x 1mm and a peripheral 
iridectomy performed. The scleral flap was sutured 
back using two 10/0 nylon stitches at the two corners. 
The conjunctival flap was also then sutured with 
10/0 nylon. All the patients were followed up 
regularly and their IOP assessed at 01 month. The 
mean IOP was then calculated for all the patients as 
a measure of success of following this treatment 
protocol.  
Results: Majority (61.9%) were females.  Mean age 
at presentation was 52.6 +8.7 years. Mean 
preoperative IOP was 37.2 +8.8 mmHg and mean 
postoperative IOP at one month was 15.2 +3.7 
mmHg. There was no or minimal hemorrhage 
peroperatively. Hypotony was seen in 25%. 
Conclusion: Intravitreal Bevacizumab prior to 
trabeculectomy with MMC in neovascular glaucoma 
is a safe and successful option. 
 
Introduction 
Neovascular glaucoma (NVG) is a severe form of 
secondary glaucoma characterized by proliferation of 
fibro vascular tissue in the anterior chamber 
angle.1 NVG can present through either a secondary 
open-angle or secondary closed-angle mechanism 
depending on the extent of neovascularization. It can 
be a potentially blinding and painful condition.1 
It is almost always caused by retinal ischemia. 
Neovascular glaucoma is usually refractory to medical 
therapy alone. Surgical approaches to managing this 
complicated form of glaucoma have evolved over the 
past few decades while often still resulting in a 
guarded visual prognosis and failed surgical results. 
Trabeculectomy has often been performed to treat this 
condition but the results have been variable even with 
Mitomycin C (an antimetabolite) as an adjunct. The 
new vessels on the iris are a major concern in the 
failure of these procedures.  In light of the association 
of vascular endothelial growth factor (VEGF) with 
retinal ischemia, and its role in new vessel formation, 
the advent of anti-VEGF drugs is proving to be a 
welcome addition in the treatment strategy for this 
potentially devastating condition.2-5 
 
Patients  and Methods 
In this case control study, performed at Department of 
Ophthalmology Holy Family Hospital and  a private 
eye surgery hospital, between December 2013 to April 
2015, 21 eyes of 21 patients with NVG, irrespective of 
the primary pathology were selected. All of them were 
given Intravitreal Bevacizumab one to two weeks prior 
to a conventional primary trabeculectomy with 
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Mitomycin C. All eyes were then followed after 01 
month for the surgical outcome of success, which was 
an IOP of less than 21 mmHg without medication with 
a functioning bleb. Intravitreal Bevacizumab was 
given in a dose of 1.25mg/.05ml using a 29 gauge 
insulin syringe after following necessary disinfection 
and sterilization protocols approximately one to two 
weeks prior to a planned primary trabeculectomy.The 
trabeculectomy procedures were all performed under 
local anesthesia (facial and peribulbar block). A fornix 
based conjunctival flap was lifted and a 4mm x 2mm 
rectangular sclera flap raised and Mitomycin C,  in a 
concentration of 0.5mg/ml applied beneath the scleral 
and conjunctival flaps using a soaked sponge for 4 to 5 
minutes and later washed with 20ml Ringer’s Lactate 
solution. A sclerotomy was then fashioned measuring 
1.5mm x 1mm and a peripheral iridectomy performed. 
The scleral flap was sutured back using two 10/0 
nylon stitches at the two corners. The conjunctival flap 
was also then sutured with 10/0 nylon. All the 
patients were followed up regularly and their IOP 
assessed at 01 month. The mean IOP was then 
calculated for all the patients as a measure of success 
of following this treatment protocol. Patients with 
uncontrolled diabetes or hypertension, retinal 
detachment, fresh or non-resolving organized vitreous 
hemorrhage, hyphema or with history of previous 
trabeculectomy or cyclo-cryo / laser ablation were 
excluded from the study. 
Results 
The 21 eyes that were included in the study all 
belonged to different individuals. 13 (61.9 %) of them 
were females and 8 (38.1 %) were males (Table-1). 
Mean age at presentation was 52.6 ( +8.7) years. Mean 
preoperative IOP was 37.2 ( +8.8) mmHg and mean 
postoperative IOP at one month was 15.2 ( + 3.7) 
mmHg (Table-2). There was no or minimal 
hemorrhage peroperatively. Some of the eyes had 
hypotony during the initial few days. Other than that 
there were no significant postoperative complications.  
Table 1: Distribution of Patients According to 
Gender (n=21) 
Males (%) Females (%) Total (%) 
8 (38.1) 13 (61.9) 21 (100) 
 
Table 2: Pre-op/Post-op Intraoccular pressure (n=21)) 
Parameters Mean S.D 
Age (years) 52.6 8.7 
Pre-op IOP (mmHg) 37.2 8.8 
Post-op IOP (mmHg) 15.2 3.7 
 p-value = 0.004* 
*p-value <0.05 is significant  
Discussion 
The cause of NVG  except for certain rare cases is 
always retinal ischemia. Retinal ischemia triggers a 
cascade of events beginning with an inadequate 
oxygen supply to the retina cells leading to the release 
of various angiogenic factors including VEGF and 
interleukin-6. Normally VEGF levels are in 
equilibrium with pigment epithelium-derived growth 
factor (PEDF), an antiangiogenic factor. When the 
equilibrium between VEGF and PEDF is shifted in 
favor of VEGF, this promotes activation, proliferation, 
and migration of endothelial cells, leading to 
neovascularization of the anterior segment. 4, 7 
Diagnosis of NVG is primarily clinical. The earliest 
signs of NVG are tiny tufts of new vessels at the 
margin of the pupil and engorgement of major arterial 
circle of the iris. Whereas normal vessels tend to lie in 
the stroma and are radial in orientation, neovascular 
vessels appear on the surface of the iris and take on an 
irregular pattern.5,12 As the vessels migrate towards 
the angle, one can see very fine arborized vessels on 
gonioscopy, which cross over the scleral spur onto the 
trabecular meshwork. Normal vessels typically remain 
behind the scleral spur. 6, 13 The walls of these vessels 
have increased permeability due to the absence of tight 
intercellular junctions, which are prone to vascular 
leakage and variable amounts of cellular 
inflammation. 6, 7 When new blood vessels appear 
within the anterior chamber angle, aqueous outflow 
can be compromised with extension of these new 
vessels across the scleral spur and subsequent 
obstruction of the trabecular meshwork. The new 
blood vessels are usually accompanied by a fibrous 
membrane, and contraction of this membrane results 
in formation of peripheral anterior synechiae and 
progressive angle closure. 
Treatment of neovascular glaucoma has always posed 
a considerable challenge. Whichever treatment 
modality is chosen, the mainstay of management 
remains panretinal photocoagulation (PRP). Treatment 
of underlying systemic disease may improve 
neovascularization of the iris. Since elevated IOP is in 
part due to compromised trabecular meshwork 
function, aqueous suppressants (beta blockers, alpha-
agonists, carbonic anhydrase inhibitors) are likely to 
have higher efficacy. Prostaglandins may be effective 
but may also exacerbate ocular inflammation. Miotic 
agents or any other medications acting on aqueous 
outflow are usually ineffective if the angle is already 
closed. Osmotic agents may be used to clear the cornea 
for treatment or diagnosis. Adjunctive treatment with 
topical steroids may control inflammation to improve 
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outcome of subsequent surgery whereas cycloplegics 
may aid in patient comfort and improve visibility for 
PRP. 
In eyes with vision better than 20/400, most glaucoma 
specialists prefer filtering surgery or aqueous shunts 
versus cyclophotocoagulation. Regardless of the 
surgical procedure chosen, preoperative panretinal 
photocoagulation should be performed whenever 
possible. 8-10 The presence of florid neovascularization 
poses a significant risk for intraoperative and 
postoperative hemorrhage, either extra or intraocular 
11. Also, the increased permeability of these fragile 
vessels predisposes the eye to severe postoperative 
inflammation. 
While trabeculectomy offers the advantage of 
achieving lower postoperative IOP compared to 
aqueous shunts, failure to adequately resolve active 
neovascularization may ultimately lead to bleb failure 
through conjunctival scarring at the filtration site. 
Aqueous shunts bear the advantage of avoiding the 
necessity of surgical iridectomy, thereby decreasing 
the risk of intraoperative hemorrhage. In addition, 
aqueous shunts are more likely to tolerate 
intraoperative and postoperative bleeding and 
massive fibrin reaction in carrying out their function. 
However, glaucoma filtration shunts are very 
expensive and associated with a cumbersome 
technique with its own list of possible complications. 
The advent of anti-VEGF agents has led to their use in 
the form of intravitreal injections. The duration of 
suppression of iris and angle neovascularization lasts 
approximately 3-6 weeks with anti-VEGF injections, 
thereby creating a window of opportunity to allow 
procedures like PRP and trabeculectomy  to be carried 
out adequately. 11, 15 
Treating neovascular glaucoma has always been 
difficult especially with trabeculectomy because of the 
bleeding and inflammation frequently associated with 
neovascularisation which enhances the chances of 
postoperative scarring beneath the bleb resulting in 
early failure.2 Our study shows that the mean 
postoperative IOP at one month was 15.2 ( + 3.7) 
mmHg without any medication which was 
significantly lower from the mean preoperative IOP of 
37.2 ( +8.8) mmHg with maximum possible medical 
therapy (p < 0.05). This is consistent with the studies 
carried out by Kitnarong et al , Wakabayashi et al  and 
Saito et al. 12-14 Alkawas et al  in a very similar case 
series also reported similar success rate. 15 
Peroperative bleeding was very minimal in all the 
cases which confirmed the findings of previous 
reports.16 No significant postoperative complications, 
apart from hypotony in 07 eyes during the first few 
days, were encountered in any of the cases. The initial 
hypotony (IOP less than 5mmHg) which resolves 
within the first 3 to 5 days is frequently observed and 
may in fact be considered as a routine occurrence in 
the convalescent course of trabeculectomy. 
Conclusion 
Using Intravitreal Bevacizumab prior to 
trabeculectomy with Mitomycin C in neovascular 
glaucoma is a safe and successful option. 
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